CureMatch Exhibits at Precision Medicine Leaders Summit 2017
CureMatch’s decision support system is up and running and leading the way to change the landscape for Precision Medicine Leaders around the globe; with initial focus on combination therapies to empower oncologists to treat cancer using genomics.
At San Diego’s Hilton Bayfront, August 21-24, 2017, learn how CureMatch has combined super computing power and data analytics to create a decision support system that sets the bar for Precision Medicine in oncology. CureMatch is not only exhibiting but will take part in several events during the summit.
Dr. Razelle Kurzrock will be on the panel for the presentation “Biomarker “Purgatory”: Why so many Biomarkers “Discovered” but So Few Successes?”, on Tuesday the 22nd at 12:00pm.
CureMatch is also hosting a roundtable discussion.
Combination Therapy in Precision Oncology – discussion leader Amelie Boichard, Pharm.D., PhD., CureMatch. Wednesday the 23rd at 6pm.
Actionable insights for the oncologist not only saves them time but ushers in Precision Medicine for clinicians wanting to improve the standard of care. CureMatch can analyze more than 4.5 million systemic treatment options, including chemotherapy, targeted therapy, hormone therapy and/or immunotherapy agents, used either alone (monotherapy) or in combinations of 3 or more drugs. Our analysis also considers off-label options.
This is the 2nd annual Precision Medicine Leaders Summit (PMLS2017) providing key industry leaders a chance to interface and catch up on the latest technologies that continue to improve at such a rapid rate.
The opening keynote address is by Dr. George Poste – “The Complex Strategic Landscape for Precision Medicine: Cost, Convergence, Culture, Computing and Creative Destruction” will set the stage for an exciting three days of open discussion. This along with numerous headline speakers will aim to facilitate audience interaction and engagement and participating in moderated roundtable discussions on a range of topics, including pharmacogenomics, population health, genomic literacy, digital genomics and proteomics.
Laura Esserman, MD, MBA, from the University of California—San Francisco will be giving a keynote entitled, “Next Generation Clinical Trials Are Here – Are We Ready?” Dr. Esserman was named to the 2016 TIME 100 List of Most Influential People in the World. Dr. Esserman has recently launched a University of California-wide breast cancer initiative called the Athena Breast Health Network, a project designed to follow 400,000 women from screening through treatment and outcomes, incorporating the latest in molecular testing and web-based tools into the course of care.
CureMatch™, Inc. is a San Diego-based digital health company focused on personalized medicine and combination therapy in oncology. CureMatch’s Decision Support System guides oncologists in the selection of cancer drugs that are customized for individual patients based on their molecular tumor profile. CureMatch enables oncologists to become experts in precision medicine by providing them with actionable intelligence towards advanced cancer treatment options. For more information visit www.curematch.com.